AB0595 CURCUMA LONGA AND BOSWELLIA SERRATA FOR OSTEOARTHRITIS PAIN MANAGEMENT: A LITERATURE REVIEW OF SPECIFIC FORMULATED EXTRACTS FOR COMBINATION

Background:The need for safe, effective pain management for osteoarthritis (OA) is important as the number of australian people with OA is expected to grow by 30% from year 2015 to year 2030. Extracts from Boswellia serrata and Curcuma longa are described to have anti-inflammatory and analgesic properties. Clinical studies have also reported efficacy for improving joint pain and stiffness and tolerability. A combination of Boswellia serrata and Curcuma longa formulated extracts might provide benefits in OA pain management.Objectives:To review the literature describing the efficacy, safety and bioavailability of a formulated Boswellia serrata extract enriched with boswellic acids and a Curcuma longa extract formulated with piperine for OA pain management.Methods:PubMed searches for studies reporting efficacy, safety, and/or bioavailability data for Boswellia and Curcumin formulations were conducted on 4 December 2020 with no publication date limitations.Results:For the enriched Boswellia formulation, two clinical studies in OA assessing efficacy and one preclinical bioavailability study were identified1,2,3. For the curcumin formulation, 2 clinical studies were identified4,5. Two double-blind, randomized, parallel, placebo-controlled studies (each N=60) demonstrated significant improvement in Western Ontario and McMaster Universities OA index (WOMAC) pain and stiffness subscale scores in patients with knee OA receiving the enriched Boswellia formulation (100mg/d): In the first study1, a 30-day treatment with enriched Boswellia, compared with placebo, significantly reduced WOMAC pain (−23.6; placebo, −5.6; P<0.0001) and stiffness (−18.8; placebo, −3.4; P=0.0014) scores. Improvement in pain visual analog scale (VAS) score was significant versus placebo at day 5 (P<0.05). In the second study2, A 90-day treatment with enriched Boswellia also significantly improved WOMAC pain (−31.1; placebo, −8.4; P<0.0001) and stiffness (−27.7; placebo, −9.9; P<0.0001) scores versus placebo; Of note, a significant reduction in pain score and functional ability was observed as early as day 7. For the curcumin/piperine formulation, piperine was added to increase the bioavailability of curcumin in humans as established in a comparative bioavailability and pharmacokinetic study4. The results obtained in his study demonstrates that piperine enhances the oral bioavailability of curcumin without side effects. Curcumin/piperine monotherapy (350-400mg curcumin TID) was also shown to significantly reduce WOMAC, VAS and Lequesne’s pain functional index (LPFI) compared to placebo in a randomized double-blind placebo-controlled parallel-group study (N=40)5. In a sub-study that measured inflammatory biomarkers (N=40), there is no significant difference in the magnitude of changes in the inflammatory biomarkers (IL-4, IL-6, hs-CRP, TNF-α, TGF-β and mean ESR between the curcuminoid treatment group and the placebo group (p>0.05)6.Conclusion:Enriched boswellic acid and curcumin/piperine formulations demonstrate efficacy and safety for suitable treatment option: both ingredients, often cited as natural alternatives to address OA pain and stiffness could be evaluated to explore the potential benefit as a formulated combination.References:[1]Vishal et al. Int. J. Med. Sci. 2011, 8[2]Sengupta et al. Int. J. Med. Sci. 2010, 7[3]Sengupta et al. Mol Cell Biochem. 2011, 354:189-197.[4]Shoba et al. Planta Med. 1998 May;64(4):353-6[5]Panahi et al. Phytother. Res. 28: 1625–1631 (2014).[6]Rahimnia A-R et al. Drug Res 2015; 65: 521–525.Disclosure of Interests:Vidhu Sethi Employee of: Employee of GSK Consumer Healthcare, Kamran Siddiqui Employee of: Employee of GSK Consumer Healthcare, Manohar Garg: None declared.

The dynamics of attitudes towards hygiene after the onset of the COVID-19 pandemic — results of an international study

GSK Consumer Healthcare and IPSOS conducted an international survey to examine how people in different countries changed their lifestyle as well as health and hygiene habits during the COVID-19 pandemic. Numerous respondents reported more frequent mouthwash usage, brushing their teeth, washing their face and hands.

OP0327 EVALUATION OF THE ARTIFICIAL INTELLIGENCE SYSTEM ACCURACY IN DETERMINING THE RADIOGRAPHIC STAGE OF KNEE OSTEOARTHRITIS

Background:Within the last decade, rapid development of artificial neural networks and machine reading programs and their introduction into medical practice is reported [1,2,3]. Recently, an innovative program, based on the artificial intelligence (AI) technologies (a neural network and machine reading) that analyses knee X-ray images for determining the radiographic stage of OA was created. It was launched on the Osteoscan.ru website and is available for use by patients and doctors.Objectives:to validate the system ability to accurately stage OA through machine interpretation of standard knee radiographs.Methods:Initially, 1300 x-rays of both knee joints where used to teach the neural network. Of these, 350 were presented in the form of film scans, 950 in the DICOM format.The accuracy of the system in recognition of OA stage by knee radiographs was evaluated on a quality control sample of 130 cases (of all 1300). Independently, the radiographs were assessed by certified radiologists (considered the “gold standard”) and the System.Results:In 124 out of 130 cases the conclusion of a specialist and the System was the same, which represents 95.4% predictive power. Coincidence or discrepancy is a qualitative attribute, so, the accuracy of the estimation was calculated. Assuming a discrepancy of 0, and coincidence - of 1, µ = 0,954, the standard error sp= 1.8%. It can be concluded that in 95% of cases the accuracy of the system assessment will be in the range from 91.8% to 99%.Conclusion:Osteosan is a program developed on the base of AI technologies, analyzes radiographic images of the knee joints for determining OA stage. It provides high accuracy in OA stage determining by assessing knee radiographs, in 95% of cases, the accuracy of the system varies from 91.8% to 99%.References:[1]Fischl B, Salat DH, van der Kouwe AJ, Makris N, Ségonne F, Quinn BT, Dale AM. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23 Suppl 1:S69-84[2]Faust O, Acharya U R, Ng EY, Ng KH, Suri JS. Algorithms for the automated detection of diabetic retinopathy using digital fundus images: a review. J Med Syst. 2012; 36(1): 145-57.[3]Balyen L, Peto T. Promising Artificial Intelligence-Machine Learning-Deep Learning Algorithms in Ophthalmology. Asia Pac J Ophthalmol (Phila). 2019; 8(3): 264-272.Disclosure of Interests:Olga Georginova Speakers bureau: GlaxoSmithKline Consumer Healthcare, Margarita Kobzar Employee of: GSK Consumer Healthcare

Exchange rate pass-through into consumer healthcare prices in Colombia

The exchange rate pass-through into the consumer price index on healthcare goods and services was measured by estimating a FAVAR model for Colombia. Results provide evidence of an incomplete and heterogeneous effect. There is no indication of transmission to the services or insurance indexes, but there is a significant effect on the medicines and devices indexes that have implications for out-of-pocket expenditure. Therefore, this indicates that the Colombian healthcare system effectively protects consumers from exchange rate volatility, but may need to design policies to protect consumers from price rises in medicines and goods that are not covered by the national benefits package.

INSIDE INDUSTRY

Korea’s biotech industry output topped 10 trillion won in 2017. Japan’s plan to revolutionise healthcare sector with tech. World’s first multiple cancer blood test to be available in India. GSK and Pfizer to form new world-leading consumer healthcare joint venture. GSK to buy oncology drugmaker Tesaro for US$5.1 billion.

INSIDE INDUSTRY

NRGene delivers first-ever food potato genomes. CMC Biologics announces development and manufacturing agreement with Harpoon Therapeutics. Typhoid vaccine prequalified. Clearbridge BioMedics’ ClearCell FX1 system achieves U.S. FDA listing. Singapore eDevelopment names Dr Roscoe Moore as senior scientific adviser to its biomedical arm. Varian Halcyon treatment system receives Taiwan FDA approval. Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration. AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics. Illumina Launches iSeq 100 Sequencing System. iGENE Laboratory granted licence by MOH to perform non-invasive prenatal test in Singapore. Clarivate Analytics appoints new president for life sciences division. Watsons partners with ChromaDex, to launch TRU NIAGEN in Singapore. Colorcon, Inc. transforms sugar coating process with new Opadry System. GSK Consumer Healthcare appoints Filippo Lanzi as head for Asia Pacific. Chugai obtains approval for TECENTRIQ for treatment of unresectable, advanced or recurrent non-small cell lung cancer. Historic deal signed between Panacea Biotec and Serum Institute of India. me+ to partner Singapore Clinical Research Institute on new innovative healthcare solutions.

25 healthcare mobile apps for consumers

Purpose The purpose of this paper is to provide a curated sample of consumer healthcare mobile apps that can be recommended to library patrons for obtaining health-related information and/or monitor and track their health. Design/methodology/approach Various health and medical apps listed on major app stores have been explored to address diverse consumer health and medical needs. Findings Healthcare mobile apps are increasingly being used by patients and consumers. Originality/value This paper examines some mobile apps that consumers are using as healthcare tools or for finding health information.

Threat, efficacy and message framing in consumer healthcare

Purpose The purpose of this paper is to empirically examine the interactive effects of message framing, perceived threat and efficacy appeals on attitudes/intentions toward consumer healthcare communications, particularly, cataract surgery. Design/methodology/approach This paper develops two conceptual models dealing with threat, efficacy and framing and tests them with data collected from two field experiments. Findings The results reveal that high efficacy messages in combination with high threat or loss-framed messages have a significant positive influence on consumer attitudes and intentions in the consumer healthcare arena. Practical implications The findings have managerial value and public policy implications for healthcare officials in developing effective communications material. Specifically, this paper recommends that high threat, high efficacy and loss-framed efficacy messages be used. Originality/value This research extends previous work by demonstrating the effectiveness of threat appeals and framing on consumer attitudes and intentions to undergo cataract surgery. It also demonstrates the use of communication models in the healthcare domain.